Evenity (Romosozumab) Dosing in Hepatic Impairment

Why the FDA Label Is Silent on Hepatic Impairment

Romosozumab's prescribing information contains no hepatic impairment section because Amgen did not conduct a dedicated pharmacokinetic study in patients with liver dysfunction. This omission is standard for monoclonal antibodies. The FDA label for Evenity addresses renal impairment (no dose adjustment needed) but does not mention hepatic impairment at all.

The reason is pharmacokinetic. Monoclonal antibodies like romosozumab are large proteins (approximately 149 kDa) that are not substrates for cytochrome P450 enzymes or hepatic transporters. Their elimination occurs through receptor-mediated endocytosis and proteolytic degradation in the reticuloendothelial system, a process distributed across multiple tissues including spleen, lymph nodes, and liver [1]. A 2010 review in the Journal of Clinical Pharmacology established that for therapeutic antibodies cleared by target-mediated disposition and nonspecific IgG catabolism, hepatic impairment alone is unlikely to alter systemic exposure meaningfully [2].

This contrasts sharply with small-molecule osteoporosis drugs like raloxifene, which undergoes extensive first-pass hepatic glucuronidation and carries explicit warnings against use in hepatic impairment. Romosozumab does not share this vulnerability.

How Romosozumab Works: The Sclerostin Pathway

Romosozumab is the first and only monoclonal antibody that inhibits sclerostin, a glycoprotein secreted primarily by osteocytes. Sclerostin acts as a negative regulator of the Wnt signaling pathway. When sclerostin binds to LRP5/6 co-receptors on osteoblast precursors, it suppresses bone formation. By neutralizing sclerostin, romosozumab activates the canonical Wnt/β-catenin pathway, producing a dual effect: rapid increases in bone formation markers and simultaneous, more gradual decreases in bone resorption markers [3].

This dual mechanism is unique. Bisphosphonates and denosumab are purely antiresorptive. Teriparatide and abaloparatide are purely anabolic. Romosozumab is the only approved agent that does both simultaneously. In the FRAME trial (N=7,180), romosozumab increased lumbar spine BMD by 13.3% at 12 months compared to 0.0% with placebo, a rate of gain unmatched by any other osteoporosis therapy [4].

The liver plays no known role in sclerostin production or clearance. Sclerostin is produced by osteocytes embedded in mineralized bone matrix. Its circulating levels are influenced by mechanical loading, PTH, and estrogen status, not by hepatic function [3]. This means the pharmacodynamic target of romosozumab operates independently of liver health.

Pharmacokinetic Profile and Why Liver Disease Likely Does Not Matter

After subcutaneous injection of 210 mg, romosozumab reaches peak serum concentration (Cmax) in approximately 5 days. Steady-state is achieved by month 3 with monthly dosing. The estimated mean steady-state trough concentration is 22.2 ± 12.3 mcg/mL. Bioavailability after SC injection is approximately 81% [1].

Elimination follows nonlinear, target-mediated disposition. At lower concentrations, sclerostin-bound romosozumab is internalized and degraded rapidly (apparent clearance is higher). At therapeutic concentrations, sclerostin binding saturates and clearance slows, yielding an effective half-life of approximately 12.8 days [1]. Neither pathway involves hepatic oxidation, conjugation, or biliary excretion.

The FDA's 2020 guidance on pharmacokinetics in patients with impaired hepatic function explicitly states that dedicated hepatic impairment studies are generally not needed for therapeutic proteins eliminated by proteolytic degradation [5]. Amgen's decision to omit this study from the romosozumab development program aligns with this regulatory framework.

Body weight is the most significant covariate affecting romosozumab exposure. In the population PK analysis submitted to the FDA, patients weighing over 105 kg had approximately 20-28% lower exposure compared to patients weighing 60-80 kg. Hepatic biomarkers (ALT, AST, bilirubin) were not identified as significant covariates [1].

Liver Safety Data from Key Trials

Neither the ARCH trial (N=4,093) nor the FRAME trial (N=7,180) reported hepatotoxicity as a safety signal [4][6]. In ARCH, which compared romosozumab to alendronate followed by alendronate in both arms, serious adverse event rates were similar between groups during the initial 12-month romosozumab phase. Liver enzyme elevations were not listed among adverse reactions occurring at ≥2% incidence [6].

Post-marketing pharmacovigilance data through the FDA Adverse Event Reporting System (FAERS) have not identified a hepatotoxicity signal for romosozumab. This is consistent with the safety profile of other therapeutic monoclonal antibodies, where drug-induced liver injury (DILI) is rare. Denosumab, another bone-targeted monoclonal antibody, carries a similar absence of hepatic warnings [7].

One practical consideration: patients with advanced cirrhosis frequently develop hepatic osteodystrophy, a complex form of metabolic bone disease characterized by both osteoporosis and osteomalacia. In a 2021 meta-analysis published in Osteoporosis International, the pooled prevalence of osteoporosis among patients with chronic liver disease was 24.7% (95% CI 19.8-30.2%) [8]. These patients represent a population with genuine clinical need for potent bone anabolic therapy.

Clinical Decision-Making for Patients with Liver Disease

The absence of formal hepatic impairment data does not mean romosozumab is contraindicated in liver disease. Clinicians should evaluate three domains before prescribing:

Domain 1: Cardiovascular risk. The FDA boxed warning states romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year [1]. Patients with advanced liver disease, particularly those with cirrhotic cardiomyopathy or portal hypertension, may carry elevated baseline cardiovascular risk. The ARCH trial found higher rates of serious cardiovascular events with romosozumab (2.5%) versus alendronate (1.9%) during the 12-month treatment period, though the absolute difference was small and the trial enrolled a population with high baseline fracture risk [6]. For patients with Child-Pugh B or C cirrhosis, the cardiovascular risk-benefit ratio deserves individual assessment.

Domain 2: Bone disease etiology. Hepatic osteodystrophy involves vitamin D deficiency (impaired 25-hydroxylation), hypogonadism, and chronic inflammation. Before starting romosozumab, clinicians should correct 25-hydroxyvitamin D levels to ≥30 ng/mL and ensure adequate calcium intake (1,000-1 to 200 mg/day), as recommended by the Endocrine Society's 2024 guideline on osteoporosis management [9]. In patients with cholestatic liver disease, fat-soluble vitamin absorption may be impaired, requiring higher replacement doses or parenteral supplementation.

Domain 3: Monitoring capacity. Romosozumab produces rapid, measurable changes in bone turnover markers. P1NP (a formation marker) typically doubles within the first month. CTX (a resorption marker) decreases by 30-50% over 12 months [4]. These markers remain valid in liver disease, though P1NP may be mildly elevated at baseline in patients with hepatic fibrosis due to collagen turnover. Clinicians should obtain baseline P1NP and CTX before the first dose to enable meaningful trend monitoring.

Dosing Protocol: No Modification Required

The standard romosozumab dosing protocol applies to patients with hepatic impairment:

• Dose: 210 mg administered as two separate subcutaneous injections of 105 mg each, given at the same visit
• Frequency: Once monthly for 12 consecutive months
• Injection sites: Abdomen, thigh, or upper arm; rotate sites between the two injections
• Duration: The anabolic window closes after 12 months as anti-drug antibodies and sclerostin rebound diminish efficacy. Do not extend beyond 12 doses.
• Transition therapy: Follow romosozumab with an antiresorptive agent (denosumab or a bisphosphonate) to maintain BMD gains. The ARCH trial protocol transitioned all patients to alendronate 70 mg weekly after the romosozumab phase [6].

For patients with cirrhosis who cannot tolerate oral bisphosphonates (due to esophageal varices or gastropathy), transitioning to denosumab 60 mg SC every 6 months or zoledronic acid 5 mg IV annually are appropriate alternatives. Zoledronic acid requires adequate renal function (CrCl ≥35 mL/min).

How Romosozumab Compares to Other Osteoporosis Agents in Liver Disease

No osteoporosis therapy has undergone a dedicated study in patients with hepatic impairment. The table below summarizes the hepatic considerations for each major drug class:

Bisphosphonates (alendronate, risedronate, zoledronic acid): Not hepatically metabolized. No dose adjustment. Oral formulations may be problematic in patients with esophageal varices. Zoledronic acid avoids this issue.

Denosumab (Prolia): Monoclonal antibody. Same proteolytic clearance as romosozumab. No hepatic dose adjustment. No hepatotoxicity signal [7].

Teriparatide (Forteo) and abaloparatide (Tymlos): Peptide hormones cleared by non-specific proteolysis in liver and kidney. Teriparatide's label notes that patients with hepatic impairment were not studied, though exposure increases are unlikely given the clearance mechanism [10].

Raloxifene (Evista): SERM metabolized by hepatic glucuronidation. Explicitly contraindicated in hepatic impairment due to potential for increased drug exposure and hepatotoxicity risk.

Romosozumab (Evenity): Monoclonal antibody. Proteolytic clearance. No hepatic dose adjustment. The cardiovascular boxed warning, not hepatic metabolism, is the primary prescribing consideration in complex patients.

Among these options, romosozumab offers the most rapid BMD gain. In the FRAME trial, the 13.3% lumbar spine BMD increase at 12 months exceeded the gains seen with teriparatide (~9% at 18 months) and denosumab (~6.5% at 12 months) [4]. For patients with severe hepatic osteodystrophy and high fracture risk, this rapid efficacy may justify the 12-month treatment course, provided cardiovascular risk is acceptable.

Special Populations Within Hepatic Disease

Non-alcoholic/metabolic-associated steatotic liver disease (MASLD): The most common form of chronic liver disease affects approximately 30% of adults globally. Patients with MASLD frequently have metabolic syndrome, obesity, and type 2 diabetes, all of which carry cardiovascular risk that intersects with romosozumab's boxed warning. A 2023 study in Hepatology found that MASLD patients with significant fibrosis (F2+) had 2.1-fold higher fracture risk compared to those without fibrosis [11]. These patients may benefit most from romosozumab's rapid bone-building capacity but require careful cardiovascular screening before initiation.

Alcoholic liver disease: Chronic alcohol use independently reduces bone formation through direct toxic effects on osteoblasts. Patients with alcohol-related liver disease therefore have compounded bone loss from both hepatic and toxic mechanisms. Romosozumab's ability to stimulate osteoblast differentiation through the Wnt pathway may be particularly relevant, though no trial data exist in this subgroup.

Post-transplant osteoporosis: Liver transplant recipients lose 2-6% of BMD in the first 6-12 months post-transplant due to high-dose immunosuppression. Romosozumab has not been studied in transplant populations. Theoretical concerns include the Wnt pathway's role in hepatocyte regeneration and potential interactions with immunosuppressive regimens, though no clinical evidence supports these concerns to date [12].

Monitoring Recommendations

For all patients on romosozumab, the 2024 Endocrine Society guideline recommends baseline and follow-up DEXA scans and bone turnover markers [9]. For patients with coexisting liver disease, consider these additions:

• Baseline labs: P1NP, CTX, 25-hydroxyvitamin D, calcium, albumin, comprehensive metabolic panel, CBC
• Month 3: P1NP (expect at least a 50% increase from baseline to confirm anabolic response)
• Month 6: Comprehensive metabolic panel to monitor hepatic function trends
• Month 12: DEXA (lumbar spine and total hip), P1NP, CTX; plan transition to antiresorptive therapy
• Cardiovascular screening: ECG and lipid panel at baseline. For patients with MASLD or cirrhosis, consider coronary artery calcium scoring or cardiology consultation if 10-year ASCVD risk exceeds 7.5%

Romosozumab requires subcutaneous injection at a healthcare facility or trained self-administration. Each monthly dose uses two prefilled syringes. Store refrigerated at 2-8°C; allow 30 minutes to reach room temperature before injection. Do not shake [1].